Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms
New York, USA, July 15, 2025 (GLOBE NEWSWIRE) — Endometrial Cancer Clinical Trial Pipeline Insights: 50+ Companies Shaping Future Treatment Paradigms | DelveInsight
Endometrial Cancer is a type of cancer that begins in the lining of the uterus, most commonly affecting postmenopausal women. Rising prevalence due to increasing obesity rates and aging population, along with advancements in targeted therapies and early diagnostic tools, are key factors driving market growth.
DelveInsight's 'Endometrial Cancer Pipeline Insight 2025' report provides comprehensive global coverage of pipeline endometrial cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the endometrial cancer pipeline domain.
Key Takeaways from the Endometrial Cancer Pipeline Report DelveInsight's endometrial cancer pipeline report depicts a robust space with 50+ active players working to develop 55+ pipeline endometrial cancer drugs.
active players working to develop pipeline endometrial cancer drugs. Key endometrial cancer companies such as Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics , Leap Therapeutics , Mersana Therapeutics, MacroGenics, Accent Therapeutics, Shanghai Henlius Biotech, Imvax, and others are evaluating new endometrial cancer drugs to improve the treatment landscape.
and others are evaluating new endometrial cancer drugs to improve the treatment landscape. Promising pipeline endometrial cancer therapies, such as Selinexor, Abemaciclib, NP137, TORL-1-23, COM 701, Envafolimab, EG-007, Prexasertib, E7386, DM002, HB0025, AMT-151, CTIM-76, Sirexatamab (DKN-01), XMT-1660, MGC026, DHX9 (ATX-559), HLX17, IEC-001, and others, are in different phases of endometrial cancer clinical trials.
and others, are in different phases of endometrial cancer clinical trials. In June 2025, Daiichi Sankyo announced the first patient had been dosed in the DESTINY-Endometrial01 clinical trial evaluating Enhertu (trastuzumab deruxtecan) in combination with rilvegostomig or Merck's Keytruda (pembrolizumab) as a first-line treatment for patients with HER2-expressing (IHC 3+/ 2+), mismatch repair proficient (pMMR) primary advanced or recurrent endometrial cancer.
In May 2025, Kaida BioPharma announced it had entered into a manufacturing agreement with Northway Biotech, Inc., an end-to-end biologics Contract Development and Manufacturing Organization (CDMO), for the manufacturing of lead product candidate, KAD101.KAD101, a novel biologic prolactin receptor antagonist, is being initially developed for the treatment of platinum-resistant ovarian cancer (PROC) with expansion opportunities into endometrial, uterine, and breast cancers.
In May 2025, PRISM BioLab, Co. Ltd. announced that the analysis of a combination study of E7386 created through collaboration research with Eisai Co., Ltd., and Lenvatinib mesylate will be presented by Eisai at the American Society of Clinical Oncology (ASCO) Congress 2025, held in Chicago, USA from May 30 to June 3, 2025. To determine the optimal dose of E7386 in combination with Lenvatinib in the open-label Phase Ib study (NCT04008797), expansion cohort of advanced endometrial cancer patients who progressed following platinum-based chemotherapy and anti-PD (L)1 immunotherapy have been implemented by Eisai, and the enrollment of 30 patients was completed.
In March 2025, Faeth Therapeutics and The GOG Foundation, Inc. (GOG-F) announced that the first patient has been dosed in its Phase II combination trial of PIKTOR, which is FTH-001 (serabelisib) and FTH-003 (sapanisertib) with paclitaxel. The trial is the most advanced of its kind to investigate a novel approach of dual PI3Kɑ-mTORC1/2 inhibition targeting cancer metabolism in patients with endometrial cancer.
In February 2025, Acrivon Therapeutics announced that the FDA had granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer.
In December 2024, Repare Therapeutics Inc. reported positive data from its MYTHIC Phase I gynecologic expansion clinical trial evaluating the combination of lunresertib and camonsertib (Lunre+Camo) at the recommended Phase II dose (RP2D) in patients with endometrial cancer and platinum-resistant ovarian cancer (PROC) harboring lunre-sensitizing biomarkers.
In December 2024, IDEAYA Biosciences, Inc. announced that it has dosed the first patient in the IDEAYA-sponsored Phase I trial evaluating the combination of IDE161, the company's investigational, potential first-in-class, small molecule poly (ADP-ribose) glycohydrolase, or PARG, inhibitor, in combination with Merck's (known as MSD outside of the US and Canada) anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in endometrial cancer patients with high microsatellite instability (MSI-high) and microsatellite stable(MSS).
Request a sample and discover the recent advances in endometrial cancer drugs @ Endometrial Cancer Pipeline Report
The endometrial cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage endometrial cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the endometrial cancer clinical trial landscape.
Endometrial Cancer Overview
Endometrial cancer, which arises from the uterus's inner lining (the endometrium), is the most common gynecologic cancer in developed countries, with its occurrence steadily increasing. This rise is linked to factors like aging populations and growing obesity rates. Most diagnoses occur in postmenopausal women, with abnormal uterine bleeding being the most frequent symptom. Because this symptom often prompts early medical evaluation, many cases are detected at an initial stage, improving treatment success.
Several risk factors play a role in the development of endometrial cancer. Obesity, metabolic syndrome, and diabetes are key contributors, with obesity responsible for about 40% of cases. Reproductive history, such as early onset of menstruation, delayed menopause, never having given birth, and infertility, also raises risk. Genetic factors, especially Lynch syndrome, increase susceptibility. In contrast, combined oral contraceptives have been linked to a decreased risk.
Diagnosis usually involves an endometrial biopsy, often following a transvaginal ultrasound to measure endometrial thickness. However, research suggests transvaginal ultrasound can produce false-negative results, particularly in Black women, indicating that biopsy remains the definitive diagnostic method. Surgical staging, based on the International Federation of Gynecology and Obstetrics (FIGO) criteria, is essential for assessing disease extent and planning treatment.
Treatment varies by stage. Early-stage disease is generally treated with a total hysterectomy and removal of both ovaries and fallopian tubes. Additional therapies such as radiation or chemotherapy may be recommended depending on risk factors. For advanced or recurrent disease, newer treatments like immunotherapy show promise. In particular, the combination of dostarlimab (JEMPERLI) with chemotherapy has improved survival in advanced or recurrent cases. Research continues to evolve to optimize these treatment approaches and improve patient outcomes.
Find out more about endometrial cancer drugs @ Endometrial Cancer Treatment
A snapshot of the Pipeline Endometrial Cancer Drugs mentioned in the report: Drugs Company Phase MoA RoA Selinexor Karyopharm Therapeutics III Exportin 1 protein inhibitors Oral EG-007 Evergreen Therapeutics III Epidermal growth factor receptor antagonists Injectable Abemaciclib Eli Lilly and Company II Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors Oral Envafolimab Alphamab Oncology/Ascletis/3D Medicine II Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants Subcutaneous Sirexatamab (DKN-01) Leap Therapeutics II DKK1 protein inhibitors Intravenous NP137 NETRIS Pharma II Antibody-dependent cell cytotoxicity; T lymphocyte stimulants Intravenous COM 701 Compugen I/II Antibody-dependent cell cytotoxicity; CD112 receptor antagonists; T lymphocyte stimulants Intravenous XMT-1660 Mersana Therapeutics I Tubulin inhibitors Intravenous
Learn more about the emerging endometrial cancer therapies @ Endometrial Cancer Clinical Trials
Endometrial Cancer Therapeutics Assessment
The endometrial cancer pipeline report proffers an integral view of the emerging endometrial cancer therapies segmented by stage, product type, molecule type, route of administration, and mechanism of action.
Scope of the Endometrial Cancer Pipeline Report Coverage : Global
: Global Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
Mono, Combination, Mono/Combination Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Discovery, Pre-clinical, Phase I, Phase II, Phase III Therapeutics Assessment By Route of Administration: Oral, Intravenous, Subcutaneous, Parenteral, Topical
Oral, Intravenous, Subcutaneous, Parenteral, Topical Therapeutics Assessment By Molecule Type : Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy
: Recombinant fusion proteins, Small molecule, Monoclonal antibody, Peptide, Polymer, Gene therapy Therapeutics Assessment By Mechanism of Action : Exportin 1 protein inhibitors, Cyclin-dependent kinase 4 inhibitors, Cyclin-dependent kinase 6 inhibitors, Antibody-dependent cell cytotoxicity, T lymphocyte stimulants, Programmed cell death-1 ligand-1 inhibitors, Endopeptidase Clp stimulants, TNF-related apoptosis-inducing ligand receptor agonists, DKK1 protein inhibitors, Tubulin inhibitors, Epidermal growth factor receptor antagonists
: Exportin 1 protein inhibitors, Cyclin-dependent kinase 4 inhibitors, Cyclin-dependent kinase 6 inhibitors, Antibody-dependent cell cytotoxicity, T lymphocyte stimulants, Programmed cell death-1 ligand-1 inhibitors, Endopeptidase Clp stimulants, TNF-related apoptosis-inducing ligand receptor agonists, DKK1 protein inhibitors, Tubulin inhibitors, Epidermal growth factor receptor antagonists Key Endometrial Cancer Companies : Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics, Leap Therapeutics, Mersana Therapeutics, MacroGenics, Accent Therapeutics, Shanghai Henlius Biotech, Imva,x and others.
: Eli Lilly and Company, Karyopharm Therapeutics, NETRIS Pharma, TORL Biotherapeutics, Compugen, 3D Medicines, Evergreen Therapeutics, Acrivon Therapeutics, Eisai, Xadcera Biopharmaceutical (Suzhou) Co., Ltd., Huabo Biopharm Co., Ltd., Multitude Therapeutics, Context Therapeutics, Leap Therapeutics, Mersana Therapeutics, MacroGenics, Accent Therapeutics, Shanghai Henlius Biotech, Imva,x and others. Key Endometrial Cancer Pipeline Therapies: Selinexor, Abemaciclib, NP137, TORL-1-23, COM 701, Envafolimab, EG-007, Prexasertib, E7386, DM002, HB0025, AMT-151, CTIM-76, Sirexatamab (DKN-01), XMT-1660, MGC026, DHX9 (ATX-559), HLX17, IEC-001, and others.
Dive deep into rich insights for new endometrial cancer treatments, visit @ Endometrial Cancer Drugs
Table of Contents 1. Endometrial Cancer Pipeline Report Introduction 2. Endometrial Cancer Pipeline Report Executive Summary 3. Endometrial Cancer Pipeline: Overview 4. Analytical Perspective In-depth Commercial Assessment 5. Endometrial Cancer Clinical Trial Therapeutics 6. Endometrial Cancer Pipeline: Late-Stage Products (Pre-registration) 7. Endometrial Cancer Pipeline: Late-Stage Products (Phase III) 8. Endometrial Cancer Pipeline: Mid-Stage Products (Phase II) 9. Endometrial Cancer Pipeline: Early-Stage Products (Phase I) 10. Endometrial Cancer Pipeline Therapeutics Assessment 11. Inactive Products in the Endometrial Cancer Pipeline 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Key Companies 14. Key Products in the Endometrial Cancer Pipeline 15. Unmet Needs 16. Market Drivers and Barriers 17. Future Perspectives and Conclusion 18. Analyst Views 19. Appendix
For further information on the endometrial cancer pipeline therapeutics, reach out @ Endometrial Cancer Therapeutics
Related Reports
Endometrial Cancer Epidemiology Forecast
Endometrial Cancer Epidemiology Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted endometrial cancer epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Endometrial Cancer Market
Endometrial Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometrial cancer companies, including GlaxoSmithKline, Merck & Co, AstraZeneca, Karyopharm Therapeutics, Evergreen Therapeutics, Incyte Corporation, among others.
Advanced Endometrial Cancer Pipeline
Advanced Endometrial Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key advanced endometrial cancer companies, including Incyte Corporation, Byondis B.V., Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Ability Pharmaceuticals SL, Zymeworks Inc., AstraZeneca, Eli Lilly and Company, Pfizer, Karyopharm Therapeutics, Genentech, Eli Lilly and Company, Genentech, Inc., NETRIS Pharma, Five Prime Therapeutics, Inc., Millennium Pharmaceuticals, Inc., Novartis Oncology, Takeda, Mundipharma-EDO GmbH, Zai Lab (Shanghai) Co., Ltd., Haihe Biopharma Co., Ltd., Xencor, Compugen Ltd, Checkpoint Therapeutics, Inc., Celon Pharma SA, Dragonfly Therapeutics, among others.
Endometriosis Pipeline
Endometriosis Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometriosis companies, including Enteris BioPharma, Bayer, Hope Medicine, Tiumbio, Organon, among others.
Endometriosis Pain Market
Endometriosis Pain Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometriosis pain companies, including Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, among others.
Endometriosis Pain Pipeline
Endometriosis Pain Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key endometriosis pain companies, including Ferring Pharmaceuticals, ObsEva SA, Myovant Sciences, Hope Medicine (Nanjing) Co., Ltd, among others.
DelveInsight's Pharma Competitive Intelligence Service: Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.
Other Business Pharmaceutical Consulting Services
Healthcare Conference Coverage
Pipeline Assessment
Healthcare Licensing Services
Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our Due Diligence Case Study
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Tom's Guide
an hour ago
- Tom's Guide
I drank lemon balm tea every day for a week to see if it could reduce stress and aid digestion — here's my verdict
If you've been around me for more than 90 seconds, you'll know that the last word anyone would use to describe me is 'calm.' If you're around me with my toddler and dog in tow, you'd probably recommend I take up yoga, or wonder how one person gets through the day surrounded by such chaos. With this in mind, when I heard about the viral TikTok trend of drinking lemon balm tea to reduce stress and anxiety, I decided to give it a try for a week to see if I noticed any difference. Read on to find out what happened. According to recent studies, lemon balm tea offers several benefits for both mental and physical well-being. Lemon balm is a fragrant herb from the mint family, characterized by its lemon-scented leaves. It has been found to have antiviral properties, as well as being anti-inflammatory. One of the most well-researched benefits of consuming lemon balm is its calming effect on the nervous system. This is said to reduce feelings of stress, anxiety, and nervousness. As well as helping you feel less stressed, lemon balm is thought to boost your mood and improve cognitive function and memory. Lemon balm is often used as a natural remedy for conditions such as insomnia and sleep disturbances, due to its calming properties. It's often paired with ingredients like camomile to help you fall asleep more easily and improve your overall sleep quality. Lemon balm is sometimes used in natural remedies for colic thanks to its ability to soothe digestive issues. It can also help with bloating, indigestion, gas and stomach cramps. Lemon balm is also used in topical ointments that treat cold sores (HSV-1) thanks to its antiviral properties. Get instant access to breaking news, the hottest reviews, great deals and helpful tips. As a reminder, while lemon balm tea is considered safe to drink for most people, you should always check with your doctor if you're on regular medication, or if you're pregnant or breastfeeding. Possible side effects associated with the consumption of lemon balm include headaches, nausea, vomiting and diarrhea. If you notice any of these side effects, stop taking lemon balm immediately. Was lemon balm tea the secret to feeling calmer? Here's what happened when I committed to drinking lemon balm tea every day for a week. Before popping the kettle on, I had to find lemon balm to drink. I keep a fresh mint plant in my garden, so I assumed I'd be able to buy a lemon balm plant in my local supermarket, and that I'd be able to stew the leaves in my teapot. Unfortunately, it was a little trickier to find, so I ended up having to buy dried leaves on the internet instead. I also found a 'happy' tea blend which contained lemon balm, turmeric and apple. In my first few days, I committed to sipping lemon balm at my desk. I usually drink peppermint tea, and the lemon balm tasted very similar. Plus, this article gave me more of an excuse to step away from my desk for a tea break. While I wasn't immediately feeling much calmer, I did need to pee more. As well as being full of antioxidants, drinking more tea means more water. It was convenient that I was doing this challenge during a heatwave here in the UK, so sipping on a couple of cups of tea during the day helped me drink more water and avoid dehydration. Plus, another benefit is that lemon balm tea is naturally caffeine-free. I found I was drinking less coffee, which is always a good thing, as too much leaves me feeling even more anxious. By the end of the week, I was fully on board with lemon balm tea and could quite easily make the switch from peppermint. I liked the taste and switched to my 'happy tea' blend when I wanted something a little punchier. I didn't notice any differences in my digestion, but I don't often suffer from bloating or indigestion. While I'm not sure my nervous system felt any calmer, I did find that the ritual of stepping away from my desk and making a tea, or sitting down with one after getting my son to bed, helped me carve out moments of calm during a very busy day. I'm going to continue sipping lemon balm tea, so maybe by the end of the month, I'll be an Instagram-perfect mum, finding calm in the chaos. Until then, I'll keep taking deep breaths when my toddler throws his dinner at the kitchen wall. Follow Tom's Guide on Google News to get our up-to-date news, how-tos, and reviews in your feeds. Make sure to click the Follow button.
Business Upturn
3 hours ago
- Business Upturn
Guizhou Upgrades 'Computing Power Capital': Core Zone of 'China Data Valley' Builds New Digital Economy Heights
By GlobeNewswire Published on July 20, 2025, 07:29 IST GUIYANG, China, July 20, 2025 (GLOBE NEWSWIRE) — 'Guiyang Big Data Hub Reaches Milestone: 1,355 Enterprises Drive Digital Economy Surge with ¥69 Billion Output.' As the flagship project of China's first national big data pilot zone, the Guiyang Big Data Science and Innovation City has achieved remarkable progress in three years. Official data from the Guizhou government shows that by 2024, the park attracted 1,355 enterprises, with big data firms accounting for 60%, achieving annual service revenue of ¥69 billion (a 6.44% year-on-year increase) Breakthrough in Data Assetization Guizhou Data Treasure Network Technology Co., Ltd. recently assisted Wanfenglin Scenic Area in completing the first case of data asset accounting in Guizhou's cultural tourism industry. By integrating merchant operations and tourist consumption data, the company designed multiple data products that not only helped the scenic area secure a 100 million yuan credit line from Guizhou Bank but also contributed to its successful upgrade to a national 5A-level tourist attraction. Zhou Lin, a partner at Data Treasure, stated that this case has spurred more cultural tourism enterprises to engage in data assetization collaborations. Computing Power Empowers the Film Industry The Gui'an New Area Supercomputing Center has provided rendering services for over 100 films, including The Battle at Lake Changjin and The Wandering Earth. Equipped with 1,000 high-performance GPUs and a computing capacity of 300 petaflops per second, the center can reduce rendering tasks that traditionally took 600 years to just a few months. The 2024 Spring Festival blockbuster Nezha: The Devil's Child's Chaos also benefited from the center's computing power. Continuous Optimization of the Business Environment The Science and Innovation City's Enterprise and Talent Service Center has innovated a 'one-network governance' model, resolving 1,489 corporate requests with a completion rate of 98.41%. By establishing a four-tier talent housing system, the zone has developed a unique investment attraction model combining 'computing power + fund' strategies. In 2025, the plan is to attract 445 new enterprises and commence construction on 2.68 million square meters of core-area projects. The zone, currently holding 'Guizhou Software Park' designation, is pursuing national-level recognition while focusing on three strategic clusters: digital economy, advanced manufacturing, and new energy materials. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
20 hours ago
- Business Upturn
Globe Civil Projects bags Rs 172.99 crore NBCC contract for Central University of Punjab development
By Aman Shukla Published on July 19, 2025, 20:08 IST Last updated July 19, 2025, 20:08 IST Globe Civil Projects Limited has secured a significant new order from NBCC (India) Ltd. worth ₹172.99 crore. The contract involves the development of key infrastructure and buildings for the Central University of Punjab, located in Village Ghudda, Bathinda district, Punjab. The project will be executed on an Engineering, Procurement, and Construction (EPC) basis and includes the construction of a range of academic and residential facilities, such as: A 400-seater Girls' Hostel A 600-seater Boys' Hostel An Academic Block A 100-seater International Students' Hostel A Vice Chancellor's Residence And extensive external development works across the campus The project is expected to be completed in approximately 21 months. This latest win highlights Globe Civil Projects' growing reputation and execution strength in large-scale institutional and educational infrastructure projects. It also reflects the continued trust placed by leading government agencies like NBCC in the company's ability to deliver quality EPC solutions across the country. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
